ImmunoEdge
ImmunoEdge pioneers next-generation immunopeptidomics to enhance neoepitope detection for cancer immunotherapy through a precision-driven approach.
Classification
Profile
Funding
Funding details not yet available.
Pioneering next-generation immunopeptidomics to enhance neoepitope detection for cancer immunotherapy with a precision-driven approach.
Biotech and life science companies, specifically those in clusters like bioRN.
Service fees - per-sample pricing (≈ €8,000-€15,000) depending on input amount and depth of analysis · Subscription licences - annual contracts for up to 12 runs, including analytics suite (€120k / yr) · Software licensing - proprietary data-processing pipeline sold as SaaS to CROs (€30k / yr)
Direct sales force - specialized scientific account managers targeting pharma R&D leads (Berlin & Munich hubs) · Online portal - self-service ordering of sample kits, real-time tracking, and secure data download · Scientific conferences & webinars - presence at AACR, ASCO, and Mass Spectrometry meetings to showcase case studies
bioRN Life Science Cluster.
R&D, technology development
Proprietary next-generation immunopeptidomics technology.
Developing precision-driven immunopeptidomics solutions for neoepitope detection.
Dedicated project managers - act as scientific liaisons, ensuring protocol alignment and data interpretation · Subscription-based access - tiered plans (Basic, Pro, Enterprise) granting a set number of runs per year plus analytics dashboards · Co-development programs - joint IP generation with pharma partners, creating “partner-owned” neo-epitope l
Competes in next-generation immunopeptidomics; differentiates through precision-driven neoepitope detection for cancer immunotherapy.
Inaccurate or insufficient neoepitope detection for effective cancer immunotherapy.
Team details not yet available.
No investors recorded yet.